Last Updated Thursday, September 18 2014
Print RSS Feed

DataLase, Colorcon Inc. Sign Licensing Agreement



Published August 15, 2007
Related Searches: additives
DataLase has entered into a license agreement with Colorcon Inc. in a move which will see the two companies working together to develop DataLase PHARMAMARK, an on-tablet marking technique for the pharmaceutical and nutritional industries. Colorcon Inc, is a world leading provider of pharmaceutical technologies and a manufacturer of specialty chemicals for related industries. Its core business is the design and technical support of advanced coating systems for pharmaceutical and nutritional supplement dosage forms, and its technological capabilities include assistance in the development of solid dosage formulations. DataLase PHARMAMARK is a patented, edible, on-tablet marking technique for recording information such as product identification numbers and markings (human readable or bar codes), unique product logos, patient details, dosage information and use by dates directly on a tablet. Tablets may be numerically serialized readily in one production campaign with no two tablets being identical. The technology will help to eliminate medication errors and counterfeiting, and increase the traceability of drugs. Colorcon has licensed DataLase patented additives for incorporation onto pharmaceutical or nutritional supplement tablets via its film coatings. The patented additive induces a color change in the film coating precisely at locations on the tablet surface exposed to a low-power, DataLase-approved CO2 laser. The DataLase PHARMAMARK additives are excipients that meet all appropriate compendial and regulatory requirements for use in these countries and they have been used in approved pharmaceuticals for many years. “We see this as a huge step forward for the industry, which will give peace of mind not only to patients, but to pharmacists and medical staff alike,” said Jean Claude Deneuville, executive vice president, corporate development at Colorcon Inc.


blog comments powered by Disqus